<DOC>
	<DOCNO>NCT00553254</DOCNO>
	<brief_summary>To assess safety efficacy PF-00299804 patient advanced lung cancer .</brief_summary>
	<brief_title>Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Advanced NSCLC Prior treatment failure least one regimen chemotherapy erlotinib gefitinib Prior treatment two chemotherapy regimen , include adjuvant treatment Measurable disease Chemotherapy , radiotherapy , biological investigational agent within 4 week baseline disease assessment Patients lack tolerance erlotinib therapy Patients know brain Metastases Patients demonstrate history presence interstitial lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>